Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2020 | Outcomes of TP53-mutant AML with venetoclax and decitabine

Marina Konopleva • 30 Nov 2020
ASH 2020
Acute Myeloid Leukemia Leukemia Decitabine Venetoclax

Marina Konopleva, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, talks on the outcomes of TP53-mutant acute myeloid leukemia patients treated with venetoclax and decitabine. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Consultancy (includes expert testimony): AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven, Kisoji
Equity ownership: Stocks, Reata Pharmaceuticals
Research funding: AbbVie, Genentech, F. Hoffman La-Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage, Astra Zeneca
Patents and royalties: Reata Pharmaceuticals

More from Marina Konopleva

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more 21:29
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
Aditi Shastri et al. • 19 Sep 2025
Anti-tumor activity and hematopoietic restoration achieved with tagraxofusp in treatment-naïve BPDCN 1:48
Anti-tumor activity and hematopoietic restoration achieved with tagraxofusp in treatment-naïve BPDCN
Marina Konopleva • 13 Jun 2025
Ongoing trials investigating novel treatments for younger and older patients with AML 3:02
Ongoing trials investigating novel treatments for younger and older patients with AML
Marina Konopleva • 13 Jun 2025

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals